Future of Aging
The companies, labs, and builders trying to turn AI-powered longevity research into real-world tools, therapies, and platforms.
The future of aging is being shaped not only by papers and lab discoveries, but also by organizations willing to build around them. This database tracks the companies, labs, and backers moving through biological age research, AI-driven discovery, prevention, and healthspan infrastructure.
Altos Labs
Cellular rejuvenation and reprogramming using partial reprogramming factors
Calico
Aging biology and longevity research
Retro Biosciences
Cellular drivers of aging and healthy lifespan extension
Unity Biotechnology
Senolytic therapies to clear senescent cells
BioAge Labs
AI-driven identification of longevity drug targets
Insilico Medicine
Generative AI for drug target discovery and molecule design
NewLimit
Epigenetic reprogramming targeting specific tissues, starting with the liver
Life Biosciences
Multiple aging pathways pursued through separate subsidiary programs
Turn Biotechnologies
mRNA-based partial cellular reprogramming
Cambrian Biopharma
Holding-company model that builds and funds separate longevity biotech subsidiaries